STRATA Skin Sciences (SSKN) announces that the American Medical Association, AMA, CPT Editorial Panel, in its May, 2025 summary of panel actions has accepted revision to CPT codes 96920-96922, expanding reimbursement eligibility for excimer laser treatments to include multiple inflammatory and auto-immune skin conditions beyond their original psoriasis indication. This change reflects over 20 years of clinical evidence and real-world use of STRATA’s XTRAC Excimer Lasers, a safe, effective, non-drug treatment for patients with chronic inflammatory and autoimmune skin diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SSKN:
- STRATA Skin Sciences’ Earnings Call Highlights Growth Amid Challenges
- STRATA Skin Sciences Reports Q1 2025 Financial Results
- Strata Skin Sciences Reports Q1 2025 Financial Results
- Strata Skin Sciences price target lowered to $14 from $16 at Ladenburg
- Strata Skin Sciences Reports Positive Earnings with Key Growth Areas